Analysts are intrested in these 5 stocks: ( (O) ), ( (GTLB) ), ( (DASH) ), ( (IOVA) ) and ( (SENS) ). Here is a breakdown of their recent ratings and the rationale behind them.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Realty Income Corporation has recently been downgraded by analyst Andrew Rosivach Cfa to a ‘Hold’ position. The company’s strong year-to-date performance has led to an increased PEG ratio, making it less attractive compared to other sectors that might catch up due to supply corrections. Despite a projected earnings growth of around 4% for 2026-27, refinancing challenges due to significant debt maturities could limit this growth. However, Realty Income’s proactive strategies and strong recession performance history provide potential for outperformance in economic downturns.
GitLab has caught the attention of analyst Blair Abernethy, who initiated coverage with a ‘Buy’ rating and a target price of $58. GitLab’s comprehensive DevOps platform is well-positioned to benefit from the growth of cloud and AI applications. The company’s focus on AI-assisted coding and its potential to commoditize code generation are seen as growth drivers. With significant upsell opportunities and impressive margin expansion, GitLab’s long-term prospects appear promising, making it an attractive investment.
DoorDash has been downgraded to ‘Hold’ by analyst John Colantuoni, despite its strong execution and growth. The company’s stock has risen by 45% year-to-date, but its valuation is considered high, and recent affordability initiatives may limit upside potential. While DoorDash is expected to deliver peer-leading EBITDA growth, the outlook for take rate expansion is murkier, leading to a more cautious stance on its future performance.
Iovance Biotherapeutics has been downgraded to ‘Sell’ by analyst Andrea Newkirk due to slower-than-expected adoption of its lead drug, Amtagvi. Operational and logistical challenges have hindered its performance, and the limited eligible patient population further complicates its commercial prospects. With potential headwinds for ex-US launches and a conservative view on future sales, Iovance faces sustained pressure on its shares in the near-to-intermediate term.
Senseonics Holdings is entering a promising phase with the U.S. launch of Eversense 365, its year-long implantable CGM. Analyst Josh Jennings has initiated coverage with a ‘Buy’ rating, highlighting Senseonics’ potential for accelerated growth in the CGM market. The company’s innovation pipeline, including the Gemini and Freedom platforms, is expected to enhance its competitive position and drive share gains, making it an exciting prospect for investors.